Compare Stocks: YDES, GLUE, JBIO, and CRVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$12.56 +0.1%	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	823,602 shs	4.46 million shs
GLUE Monte Rosa Therapeutics	$12.13 -3.7%	$16.95	$6.23 ▼ $25.77	$1.03B	1.5	1.12 million shs	1.60 million shs
JBIO Jade Biosciences	$16.94 -1.2%	$20.61	$7.29 ▼ $28.00	$1.08B	1.45	785,345 shs	2.94 million shs
YDES YD Bio	$3.19 -1.5%	$3.16	$1.70 ▼ $22.00	$225.82M	N/A	413,026 shs	535,518 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	-2.71%	-12.35%	+5.46%	+116.93%
GLUE Monte Rosa Therapeutics	0.00%	-13.79%	-17.93%	-33.75%	+90.72%
JBIO Jade Biosciences	0.00%	-5.31%	-20.21%	+0.71%	+143.74%
YDES YD Bio	0.00%	-20.25%	-33.40%	+31.82%	+318,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$12.56 +0.1%	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	823,602 shs	4.46 million shs
GLUE Monte Rosa Therapeutics	$12.13 -3.7%	$16.95	$6.23 ▼ $25.77	$1.03B	1.5	1.12 million shs	1.60 million shs
JBIO Jade Biosciences	$16.94 -1.2%	$20.61	$7.29 ▼ $28.00	$1.08B	1.45	785,345 shs	2.94 million shs
YDES YD Bio	$3.19 -1.5%	$3.16	$1.70 ▼ $22.00	$225.82M	N/A	413,026 shs	535,518 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	-2.71%	-12.35%	+5.46%	+116.93%
GLUE Monte Rosa Therapeutics	0.00%	-13.79%	-17.93%	-33.75%	+90.72%
JBIO Jade Biosciences	0.00%	-5.31%	-20.21%	+0.71%	+143.74%
YDES YD Bio	0.00%	-20.25%	-33.40%	+31.82%	+318,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	165.39% Upside
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	134.95% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	205.49% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest YDES, GLUE, JBIO, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	JBIO Jade Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/11/2026	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/10/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$45.00 ➝ $47.00
8/10/2026	JBIO Jade Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$74.00 ➝ $77.00
8/7/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $28.00
8/7/2026	GLUE Monte Rosa Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$31.00 ➝ $27.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	99.08	$0.73 per share	N/A
GLUE Monte Rosa Therapeutics	$123.67M	8.37	N/A	N/A	$3.58 per share	3.39
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-49.11%	-45.62%	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest YDES, GLUE, JBIO, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
JBIO Jade Biosciences	N/A	14.93	14.93
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
GLUE Monte Rosa Therapeutics	79.96%
JBIO Jade Biosciences	N/A
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	19.70%
GLUE Monte Rosa Therapeutics	6.40%
JBIO Jade Biosciences	23.06%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
JBIO Jade Biosciences	55	63.60 million	48.93 million	N/A
YDES YD Bio	15	70.79 million	N/A	N/A

YDES, GLUE, JBIO, and CRVS Headlines

Recent News About These Companies

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

YD Bio (NASDAQ:YDES) Stock Price Down 7.8% - Time to Sell?

September 10, 2026 | americanbankingnews.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

Yd Bio

June 25, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES, GLUE, JBIO, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$12.56 +0.01 (+0.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.50 -0.06 (-0.51%)

As of 09/18/2026 07:56 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$12.13 -0.47 (-3.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.24 +0.11 (+0.95%)

As of 09/18/2026 07:30 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Jade Biosciences NASDAQ:JBIO

$16.94 -0.20 (-1.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.91 -0.03 (-0.18%)

As of 09/18/2026 07:30 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

YD Bio NASDAQ:YDES

$3.19 -0.05 (-1.54%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.25 +0.06 (+1.88%)

As of 09/18/2026 07:55 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YDES, GLUE, JBIO, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YDES, GLUE, JBIO, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YDES, GLUE, JBIO, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES, GLUE, JBIO, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Monte Rosa Therapeutics NASDAQ:GLUE

Jade Biosciences NASDAQ:JBIO

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YDES, GLUE, JBIO, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YDES, GLUE, JBIO, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YDES, GLUE, JBIO, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES, GLUE, JBIO, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Monte Rosa Therapeutics NASDAQ:GLUE

Jade Biosciences NASDAQ:JBIO

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools